Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities
Cancer Letters · 2024-03 · 584 · 216650
DOI: 10.1016/j.canlet.2024.216650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-03. Verfasst von Sabrina Steiner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to late detection and limited treatment options. Some PDAC patients harbor alterations that qualify for targeted treatment strategies but develop acquired resistance, leading to treatment failure. We here report the ex vivo modeling of acquired drug resistance by creating a PDAC patient-derived tumor organoid (PDTO) model harboring a rare BRAF R506_K507ins VLR mutation resulting in a resistance to trametinib, a MEK inhibitor. Genomic and transcriptomic analyses revealed upregulated WNT signaling in resistant PDTO clones compared to treatment-naïve parental control cells. By combining genomic and transcriptomic analysis with a functional drug testing approach, we uncovered a de novo upregulation and circumventive reliance on WNT signaling in resistant PDTO clones. Ex vivo models such as PDTOs represent valuable tools for resistance modelling and offer the discovery of novel therapeutic approaches for patients in need where clinical diagnostic tools are currently at the limit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland.
- Department of Hematology and Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland; Medical Faculty, University of Zurich, Pestalozzistrasse 3, 8032, Zurich, Switzerland. Elect…
Zitieren
APA
Steiner, S., Pliego-Mendieta, A., Haberecker, M., Hussung, S., Kollár, A., Fritsch, R., Arnold, F., Lenggenhager, D., Planas-Paz, L., & Pauli, C. (2024). Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities. Cancer Letters, 584, 216650. https://doi.org/10.1016/j.canlet.2024.216650
Vancouver
Steiner S, Pliego-Mendieta A, Haberecker M, Hussung S, Kollár A, Fritsch R, et al. Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities. Cancer Letters. 2024;584:216650. doi:10.1016/j.canlet.2024.216650
BibTeX
@article{Steiner2024,
author = {Steiner, Sabrina and Pliego-Mendieta, Alicia and Haberecker, Martina and Hussung, Saskia and Kollár, Anna and Fritsch, Ralph and Arnold, Fabian and Lenggenhager, Daniela and Planas-Paz, Lara and Pauli, Chantal},
title = {Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities},
journal = {Cancer Letters},
year = {2024},
volume = {584},
pages = {216650},
doi = {10.1016/j.canlet.2024.216650}
}
EUVIMED